Chiasma to Report Second Quarter 2020 Results on August 10
Chiasma, a biopharmaceutical company, will host a conference call on August 10, 2020, at 5:00 PM Eastern Time to discuss its financial results for the second quarter of 2020 and provide a business update. Investors can participate by calling 855-327-6837 in the U.S. or 631-891-4304 internationally, using conference ID 10010555. A live audio webcast will also be available, with an archived replay accessible on their website for one year. Chiasma recently received FDA approval for MYCAPSSA, the first oral somatostatin analog for acromegaly patients.
- None.
- None.
NEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the quarter ended June 30, 2020 and to provide a business update.
Conference Call Details
Monday, August 10th @ 5pm Eastern Time
| Domestic: | 855-327-6837 |
| International: | 631-891-4304 |
| Conference ID: | 10010555 |
| Webcast: | http://public.viavid.com/index.php?id=141033 |
A live audio webcast of the call may also be accessed under "Events & Presentations" on the News & Investors section of the Company's website, https://ir.chiasma.com/events-presentations. An archived replay of the webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.
About Chiasma
Chiasma is focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog approved by the FDA. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com
Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com
FAQ
When will Chiasma's conference call take place?
What is the purpose of Chiasma's conference call?
How can I access the conference call for Chiasma?
What recent approval did Chiasma receive from the FDA?
Where can I find the archived webcast of Chiasma's conference call?
